Skip to content

Replimune Group, Inc.

REPL Nasdaq SEC CIK 1737953

Follow Replimune Weekly email: filings, results, news

News

9 stories filed under Replimune, grouped into ongoing threads

FDA

Thread · 3 stories

Replimune in the spotlight: Earnings loom days after FDA approval

Earnings 46 d ago 3 sources

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Markets 48 d ago

STAT+: FDA approves Replimune melanoma drug previously rejected twice

Markets 49 d ago 2 sources

More coverage

Replimune CFO Emily Hill sells $132,175 in stock for tax obligations

Markets 36 d ago

Replimune Group stock may move 5.6% on earnings release

Earnings 41 d ago

Why is Replimune stock surging today?

Markets 45 d ago

Why is Replimune stock surging today?

Markets 45 d ago

Replimune Group, Inc. (REPL) Shareholder/Analyst Call - Slideshow

Markets 48 d ago

Why is Replimune stock volatile today?

Markets 48 d ago

Profile

Headquarters: WOBURN, MA, United States
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)

Latest filings

Q1 2026 report10-Q · 14 Aug 2026

Peers

Where this page comes from

Profile · SEC EDGAR

Financials · SEC EDGAR filing dates

News · 9 stories clustered from the RSS aggregator